FRESENIUS SE&CO (FSNUY) Downgraded to “Sell” at UBS AG

UBS AG cut shares of FRESENIUS SE&CO (OTCMKTS:FSNUY) from a neutral rating to a sell rating in a research note issued to investors on Friday.

Separately, Zacks Investment Research cut shares of FRESENIUS SE&CO from a strong-buy rating to a hold rating in a research note on Tuesday, October 3rd.

FRESENIUS SE&CO (OTCMKTS:FSNUY) traded down $1.08 during midday trading on Friday, hitting $18.75. 20,758 shares of the stock were exchanged, compared to its average volume of 15,574. The company has a current ratio of 1.28, a quick ratio of 0.96 and a debt-to-equity ratio of 0.81. The firm has a market cap of $43,990.00, a PE ratio of 23.63, a PEG ratio of 1.99 and a beta of 0.61. FRESENIUS SE&CO has a one year low of $17.22 and a one year high of $22.30.

COPYRIGHT VIOLATION WARNING: “FRESENIUS SE&CO (FSNUY) Downgraded to “Sell” at UBS AG” was originally published by Sports Perspectives and is the sole property of of Sports Perspectives. If you are accessing this news story on another domain, it was illegally stolen and reposted in violation of U.S. and international trademark and copyright law. The original version of this news story can be read at


Fresenius SE & Co KGaA, a health care group, provides products and services for dialysis, hospitals, and outpatient medical care worldwide. The company operates through Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed segments. The Fresenius Medical Care segment offers products for patients with chronic kidney failure.

Receive News & Ratings for FRESENIUS SE&CO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FRESENIUS SE&CO and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply